About Sislax Pharma Private Limited
Data last updated:
Sislax Pharma Private Limited is a private limited company based in UT, Chandigarh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 26 April 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN U24232CH1995PTC016300. Its GSTIN is 06AABCS9892C1Z5 (Haryana).
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹49.99 Lakh. It is led by directors including Sunanda Gupta and Satish Bamba.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at H No 2554 Sector 35 C Chandigarh, UT, Chandigarh, India.
As per the financials filed for FY 2025, the company reported a revenue of ₹4.09 Cr, a growth of 5% compared to the previous year. For the same year it recorded a net profit of ₹11.85 Lakh (net margin 2.9%) and EBITDA of ₹18.95 Lakh (EBITDA margin 4.6%). Revenue has grown at a compounded annual rate (CAGR) of 4% over three years and 4% over five years.
The company has about 24 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹34.35 Cr and satisfied charges of ₹4.29 Cr on record. Court records list 1 case involving the company, including 1 filed against it.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sislax.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressH No 2554 Sector 35 C Chandigarh, UT, Chandigarh, India
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Sislax Pharma Private Limited
The main business activity of Sislax Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Sislax Pharma Private Limited
Sislax Pharma Private Limited is audited by PREM GARG & ASSOCIATES for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| PREM GARG & ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Sislax Pharma Private Limited
Sislax Pharma has 3 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sunanda Gupta | Director | 02 Feb 2015 | 11 Years 8 Months | Current |
| Satish Bamba | Director | 31 Oct 2017 | 8 Years 11 Months | Current |
| Usha Vig | Director | 12 Jun 2006 | 20 Years 3 Months | Current |
Financials of Sislax Pharma Private Limited FY 2025 filings available
Sislax Pharma Private Limited reported revenue of ₹4.09 Cr (up 5% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Sislax Pharma Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 4% over five years, including 5% growth in the latest year. EBITDA rose 5% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Sislax Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹18.95 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹11.85 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Sislax Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.6% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 2.9% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Sislax Pharma are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Sislax Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Sislax Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Jun 2024 | Others | ₹28.7 Cr | Open |
| 14 May 2012 | Others | ₹5.65 Cr | Open |
| 02 Mar 2005 | Canara Bank | ₹3.4 Cr | Satisfied |
| 02 Mar 2005 | Canara Bank | ₹25 Lakh | Satisfied |
| 29 Apr 2004 | Canara Bank | ₹14 Lakh | Satisfied |
Total charge records: 7 View all charges
Employees and EPFO Compliance at Sislax Pharma Private Limited
Sislax Pharma Private Limited has a workforce of 24 employees as of Sep 24, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Sislax Pharma Private Limited
Sislax Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 06AABCS9892C1Z5 | Haryana | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Legal Cases of Sislax Pharma Private Limited
Sislax Pharma Private Limited has 1 court case on record: 1 filed against it. All case is disposed. Status as checked on 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 1 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Vadodara, Gujarat | Criminal complaint | Filed against the company by Alembic Limited | Disposed |
Full case history
All 1 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit Ratings, Litigation & Regulatory Alerts for Sislax Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Sislax Pharma Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sislax Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sislax Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Sislax Pharma Private Limited
Frequently Asked Questions about Sislax Pharma Private Limited
Sislax Pharma is an active private limited company based in UT, Chandigarh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 26 April 1995 (31+ years old) and is registered under CIN U24232CH1995PTC016300.
Sislax Pharma reported revenue of ₹4.09 Cr for FY 2025 (up 5% YoY).
Sislax Pharma has 3 current directors:
- Sunanda Gupta - Director
- Satish Bamba - Director
- Usha Vig - Director
Sislax Pharma reported a net profit of ₹11.85 Lakh (net margin 2.9%) and EBITDA of ₹18.95 Lakh (EBITDA margin 4.6%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Sislax Pharma is 4% over three years and 4% over five years. In the latest year (FY 2025) revenue rose 5%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Sislax Pharma is 06AABCS9892C1Z5, registered in Haryana.
The CIN (Corporate Identification Number) of Sislax Pharma is U24232CH1995PTC016300. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Sislax Pharma has 1 court case on record: 1 filed against it.
Sislax Pharma was incorporated on 26 April 1995, making it 31+ years old. It is registered with the Registrar of Companies, Chandigarh.